Parker H Stewart - Apr 22, 2021 Form 3/A - Amendment Insider Report for IMPEL NEUROPHARMA INC (IMPL)

Role
Director
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Stock symbol
IMPL
Transactions as of
Apr 22, 2021
Transactions value $
$0
Form type
3/A - Amendment
Date filed
6/22/2021, 05:41 PM
Date Of Original Report
Apr 22, 2021
Next filing
Jun 22, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMPL Series A-2 Preferred Stock Apr 22, 2021 Common Stock 7.36K Direct F1
holding IMPL Series C-1 Preferred Stock Apr 22, 2021 Common Stock 8.79K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of the issuer's Series A-2 Preferred Stock will automatically convert on a 16.37332-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's initial public offering ("IPO"), and has no expiration date.
F2 The shares of the issuer's Series C-1 Preferred Stock will automatically convert on a 16.37332-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's IPO, and has no expiration date.

Remarks:

This amended Form 3 is being filed to report the omission of the Series A-2 preferred stock warrant and the Series C-1 preferred stock warrant reported on Table II in the Form 3 filed on April 22, 2021 as the warrants were exercised prior to the filing of the Form 3, and to increase the number of shares underlying the derivative security to reflect the earlier exercise of each respective warrant.